Growth Hormone Treatment, Metabolic Diseases
Conditions
Keywords
lipolysis, ATGL
Brief summary
Growth hormone (GH) induces fat metabolism. The mechanisms underlying the fat metabolizing effects of GH remain elusive. However, it is known that insulin suppresses fat metabolism, and GH inhibits the expression of certain insulin-dependent signaling proteins. We therefore hypothesize that the fat metabolizing effects of GH depend on abrogation of insulin-dependent signaling pathways. In order to investigate the fat metabolizing effects of GH, we'll analyze consecutive adipose tissue biopsies taken after GH exposure and GH blocking, respectively. Knowledge of the effects of growth hormone and fat metabolism can in shot-sight as well as in long-sight have great importance for the understanding of growth disorders from overweight and type 2 diabetes to malnutrition and eating disorders.
Interventions
Subjects are receiving one injection of growth hormone (Genotropin) 0,5 mg
One the placebo day the subjects are receiving injection with pegvisomant (Somavert 30 mg) to block the action of endogenous growth hormone
Sponsors
Study design
Eligibility
Inclusion criteria
* healthy males * no medication * BMI 28-35
Exclusion criteria
* known diseases * regular medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lipolytic activity measured as area under the curve (AUC) for FFA (blood sample). | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Intracellular lipolytic activity measured by an ATGL assay | 1 year |
| GH signaling gene targets in adipose tissue measured by qPCR | 1,5 years |
| Substrate metabolism as measured by indirect calorimetry | 3 months |
| GH signaling proteins in adipose tissue measured by western blotting | 1,5 years |
Countries
Denmark